Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: PTH increases from early stages of renal disease. One of the goals in pre-dialysis is the prevention of hyperphosphatemia and the maintenance of Ca levels in the normal range. The management of hyperparathyroidism in dialysis requires control of phosphorus level. In this stage, the decision to use calcimimetics and vitamin D derivatives should be made according to serum levels of Ca and phosphorus.
|
Authors | Mariano Rodríguez, María E Rodríguez-Ortiz |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 16
Issue 11
Pg. 1703-16
( 2015)
ISSN: 1744-7666 [Electronic] England |
PMID | 26159447
(Publication Type: Journal Article, Review)
|
Chemical References |
- Calcimimetic Agents
- Parathyroid Hormone
- Vitamin D
- Calcium
|
Topics |
- Calcimimetic Agents
(therapeutic use)
- Calcium
(metabolism)
- Dietary Supplements
- Humans
- Hyperparathyroidism, Secondary
(blood, drug therapy)
- Hyperphosphatemia
(drug therapy)
- Parathyroid Hormone
(blood)
- Vitamin D
(analogs & derivatives, blood, therapeutic use)
|